Based on current and previous studies, the Cur + Pip has shown promising potential as an adjunct therapy for improving liver enzyme levels and inflammatory status, particularly in overweight adults with metabolic dysfunctions such as NAFLD and metabolic syndrome. This evidence concerns the gene PIP and metabolic dysfunction-associated steatotic liver disease.